All In Biotech

Drug Trial Radar · NCT02318329

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

79

Actual

Start

Nov 2014

Primary completion

Feb 28, 2019

Study completion Jun 30, 2019

Sponsor

Lead sponsor
Five Prime Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.

Conditions

  • Advanced Solid Tumors
  • Gastric Cancer
  • Transitional Cell Carcinoma of the Bladder

Interventions

  • FPA144Drug

    FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Protocol Specified Dose-limiting Toxicities (Part 1 Only).Time frame: 4 weeks on average
  2. Number of Participants With AEs and Clinical Laboratory Abnormalities (Parts 1B and 2 Only)Time frame: 16 weeks on average

Locations

26 sites in 3 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • UCSF Helen Diller Family Comprehensive Cancer Center, Mission Bay

    San Francisco, California

  • Innovative Cancer Research Institute

    Whittier, California

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Weill Cornell Medical Center

    New York, New York

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute, LLC

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas

  • South Texas Accelerated Research Therapeutics, LLC

    San Antonio, Texas

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Gangnam Severance Hospital

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Seoul St. Mary's Hospital

    Seoul, South Korea

  • SMG-SNU Boramae Medical Center

    Seoul, South Korea

  • Chonbuk National University Hospital

    Jeonju, Jeollabuk-do, South Korea

  • China Medical University Hospital

    Taichung, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.